Ipca Laboratories (NSE:IPCALAB) Cyclically Adjusted Revenue per Share: ₹292.70 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:IPCALAB Ipca Laboratories Ltd NSE:IPCALAB
93 GF Score
Price ₹1,878.00
GF Value ₹1,596.73
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Ipca Laboratories Cyclically Adjusted Revenue per Share?

Ipca Laboratories NSE:IPCALAB +2.04% 93 Cyclically Adjusted Revenue per Share is ₹292.70 as of Mar. 2026. GuruFocus rates NSE:IPCALAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,596.73 (Modestly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Ipca Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was ₹94.159. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹292.70 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Ipca Laboratories's average Cyclically Adjusted Revenue Growth Rate was 9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-15), Ipca Laboratories's current stock price is ₹1878.00. Ipca Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹292.70. Ipca Laboratories's Cyclically Adjusted PS Ratio of today is 6.42.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ipca Laboratories was 6.50. The lowest was 4.47. And the median was 5.24.


Ipca Laboratories  (NSE:IPCALAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ipca Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1878.00/292.70
=6.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Ipca Laboratories was 6.50. The lowest was 4.47. And the median was 5.24.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Ipca Laboratories Cyclically Adjusted Revenue per Share Related Terms


Ipca Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Ipca Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ipca Laboratories Cyclically Adjusted Revenue per Share Chart

Ipca Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 268.60 292.70

Ipca Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 268.60 275.71 283.39 287.54 292.70

NSE:IPCALAB vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipca Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ipca Laboratories's Cyclically Adjusted PS Ratio falls into.


NSE:IPCALAB
93GF Score
Ipca Laboratories Ltd NSE:IPCALAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ipca Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ipca Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=94.159/164.2724*164.2724
=94.159

Current CPI (Mar. 2026) = 164.2724.

Ipca Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201103 0.000 70.768 0.000
201203 0.000 76.889 0.000
201303 0.000 85.687 0.000
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201806 34.672 111.317 51.166
201809 40.047 115.142 57.135
201812 39.815 115.142 56.804
201903 31.603 118.202 43.921
201906 42.585 120.880 57.872
201909 50.806 123.175 67.757
201912 47.966 126.235 62.419
202003 38.816 124.705 51.132
202006 60.602 127.000 78.387
202009 53.793 130.118 67.913
202012 55.570 130.889 69.743
202103 41.807 131.771 52.119
202106 61.731 134.084 75.629
202109 60.856 135.847 73.590
202112 56.359 138.161 67.011
202203 48.333 138.822 57.194
202206 62.516 142.347 72.145
202209 63.081 144.661 71.633
202212 60.928 145.763 68.665
202303 58.122 146.865 65.011
202306 62.505 150.280 68.325
202309 80.203 151.492 86.969
202312 80.914 152.924 86.918
202403 76.823 153.035 82.464
202406 82.512 155.789 87.005
202409 92.870 157.882 96.629
202412 88.497 158.323 91.823
202503 88.450 157.552 92.223
202506 90.984 159.755 93.557
202509 100.787 162.289 102.019
202512 94.301 163.281 94.874
202603 94.159 164.272 94.159

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹292.70 mean?
Ipca Laboratories (NSE:IPCALAB) has a Cyclically Adjusted Revenue per Share of ₹292.70 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ipca Laboratories and its competitors.
Is Ipca Laboratories' Cyclically Adjusted Revenue per Share too high?
Ipca Laboratories' current Cyclically Adjusted Revenue per Share is ₹292.70. Overall, Ipca Laboratories has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ipca Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Ipca Laboratories' Cyclically Adjusted Revenue per Share of ₹292.70 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Ipca Laboratories and its competitors. Ipca Laboratories's current Cyclically Adjusted Revenue per Share is ₹292.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ipca Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ipca Laboratories (NSE:IPCALAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,596.73, compared to a current price of ₹1,878.00 — trading 17.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹292.70. Ipca Laboratories' overall GF Score™ is 93/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Ipca Laboratories (NSE:IPCALAB), the current Cyclically Adjusted Revenue per Share is ₹292.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ipca Laboratories (NSE:IPCALAB) Overvalued in 2026?

Based on GuruFocus' analysis, Ipca Laboratories stock appears to be overvalued. The current stock price of ₹1,878.00 is trading 17.6% above its estimated GF Value™ of ₹1,596.73. GuruFocus considers Ipca Laboratories to be Modestly Overvalued.

Key valuation signals for NSE:IPCALAB:

  • Cyclically Adjusted Revenue per Share: ₹292.70
  • GF Value™: ₹1,596.73 vs. price of ₹1,878.00 (17.6% above fair value)
  • GF Score™: 93/100 with 6 warning signs

No single metric tells the full story. See the NSE:IPCALAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ipca Laboratories Business Description

Other Exchanges 524494:India
Address No. 48, 123 AB, 125 & 126 Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.
93GF Score

Get the complete analysis for NSE:IPCALAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,878.00
Price
₹1,596.73
GF Value